INS and diabetes mellitus: This is of relevance, since current diabetes drugs are limited to increasing secretion of endogenous insulin, reducing the reabsorption of glucose in the kidneys, preventing absorption of monosaccharides in the intestine, by lowering liver glucose production and increasing gut energy utilisation, or by directly replacing the endogenous insulin.